Fulgent Genetics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparative period is Q1 2023. Fulgent operates laboratory services and a therapeutic development business focused on oncology drug candidates.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $64.5 million | $66.2 million | Down 3% |
| Gross profit / margin | $22.1 million / 34.3% | $18.8 million / 28.4% | Margin up 5.9 percentage points |
| Operating loss | $21.8 million | $24.8 million | Loss narrowed $3.0 million |
| Net loss attributable to Fulgent | $13.5 million; $0.45 per share | $15.3 million; $0.52 per share | Loss narrowed $1.9 million |
| Operating cash flow | +$7.3 million | -$7.9 million | Improved $15.2 million |
Cash, cash equivalents, and marketable securities totaled $846.2 million at March 31, compared with $847.7 million at year-end. Cash and cash equivalents alone were $54.7 million, down from $97.5 million. Current assets were $386.5 million versus current liabilities of $75.9 million. Notes payable totaled approximately $2.9 million; the company reported no expectation of using credit facilities in the foreseeable future. Operating lease liabilities were $9.5 million and finance lease liabilities were $1.2 million.
Net cash used in investing was $47.2 million, primarily reflecting purchases of marketable securities, partly offset by maturities and sales. Financing activities used $2.8 million. The company reported $57.9 million of purchase obligations, of which $39.6 million is due within 12 months.
Material changes and management commentary
- Precision diagnostics revenue rose 34% to $37.4 million, supported by reproductive health services, expanded Beacon787 testing, and specialized oncology testing.
- Anatomic pathology revenue fell 13% to $23.1 million, which management attributed to weather issues and reimbursement-rate changes. BioPharma services fell 68% to $2.7 million, primarily due to project timing. COVID-19 revenue declined 63% to $1.3 million following cessation of testing operations at the end of March 2023.
- Cost of revenue declined 11%, and gross margin improved primarily due to product mix and lower costs following COVID-19 testing cessation and a laboratory closure. Research and development expense increased 17% to $11.4 million; therapeutic development R&D rose 66% to $4.1 million, largely due to a drug study with contract research organizations.
- Interest and other income increased to $7.6 million from $3.8 million, primarily due to higher interest rates on marketable securities. The income tax benefit declined to $0.3 million from $5.2 million; a valuation allowance limited recognition of tax benefits from net operating losses.
- One laboratory-services customer represented $12.6 million, or 20%, of Q1 revenue. Management expects operating expenses and cash use to rise with ongoing FID-007 clinical trials and investment in laboratory services, while stating available cash, equivalents, and short-term securities should cover anticipated needs for at least 12 months.
Outlook, risks, and unusual items
- Management expected enrollment in a Phase 2 study of FID-007 to begin in Q2 2024; it anticipates higher therapeutic-development R&D spending. The filing provides no specific revenue or earnings guidance.
- The company is cooperating with a Department of Justice False Claims Act investigation and an SEC investigation relating to laboratory testing, billing, and possible remuneration issues. It cannot estimate potential losses and has recorded no liability for these matters.
- HRSA is auditing reimbursements for COVID-19 tests provided to uninsured patients. Fulgent reported approximately $548.9 million of reimbursements under the program for 2020–2022; amounts that may need to be returned are uncertain, and no liability has been recorded for the audit.
- A voluntary disclosure process related to an HHS OIG advisory opinion resulted in a recorded $6.9 million liability; the ultimate amount could be lower or materially higher.
- The FDA’s final rule to phase out enforcement discretion for laboratory-developed tests was released April 29, 2024, after quarter-end. The filing describes a staged implementation over four years, possible litigation, and uncertainty around requirements and timing; compliance could increase costs or disrupt testing.
- Fulgent recorded a full goodwill impairment for its laboratory-services reporting unit in December 2023. No impairment changes were reported in Q1 2024, but management continues to monitor therapeutic-development goodwill and acquired in-process R&D.
Important facts for investors to verify
- Progress, timing, and spending for the planned FID-007 Phase 2 study.
- Growth and reimbursement trends in precision diagnostics, and customer concentration, including the customer contributing 20% of Q1 revenue.
- Developments and potential financial exposure from the DOJ and SEC investigations, HRSA audit, and voluntary disclosure.
- The FDA’s laboratory-developed-test rule, litigation or legislative developments, and implications for test approvals, costs, and access.
- Cash deployment, securities portfolio value, purchase obligations, and whether operating cash flow remains positive as investment and clinical-trial spending increase.